166 related articles for article (PubMed ID: 33581287)
1. Deguelin targets multiple oncogenic signaling pathways to combat human malignancies.
Tuli HS; Mittal S; Loka M; Aggarwal V; Aggarwal D; Masurkar A; Kaur G; Varol M; Sak K; Kumar M; Sethi G; Bishayee A
Pharmacol Res; 2021 Apr; 166():105487. PubMed ID: 33581287
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological basis and new insights of deguelin concerning its anticancer effects.
Lin ZY; Yun QZ; Wu L; Zhang TW; Yao TZ
Pharmacol Res; 2021 Dec; 174():105935. PubMed ID: 34644595
[TBL] [Abstract][Full Text] [Related]
3. Biopharmacological considerations for accelerating drug development of deguelin, a rotenoid with potent chemotherapeutic and chemopreventive potential.
Varughese RS; Lam WS; Marican AABH; Viganeshwari SH; Bhave AS; Syn NL; Wang J; Wong AL; Kumar AP; Lobie PE; Lee SC; Sethi G; Goh BC; Wang L
Cancer; 2019 Jun; 125(11):1789-1798. PubMed ID: 30933320
[TBL] [Abstract][Full Text] [Related]
4. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells.
Chun KH; Kosmeder JW; Sun S; Pezzuto JM; Lotan R; Hong WK; Lee HY
J Natl Cancer Inst; 2003 Feb; 95(4):291-302. PubMed ID: 12591985
[TBL] [Abstract][Full Text] [Related]
5. Anticancer efficacy of deguelin in human prostate cancer cells targeting glycogen synthase kinase-3 β/β-catenin pathway.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2011 Dec; 129(12):2916-27. PubMed ID: 21472727
[TBL] [Abstract][Full Text] [Related]
6. Deguelin inhibits vasculogenic function of endothelial progenitor cells in tumor progression and metastasis via suppression of focal adhesion.
Nguyen MP; Lee D; Lee SH; Lee HE; Lee HY; Lee YM
Oncotarget; 2015 Jun; 6(18):16588-600. PubMed ID: 26078334
[TBL] [Abstract][Full Text] [Related]
7. Deguelin, an Akt inhibitor, down-regulates NF-κB signaling and induces apoptosis in colon cancer cells and inhibits tumor growth in mice.
Kang HW; Kim JM; Cha MY; Jung HC; Song IS; Kim JS
Dig Dis Sci; 2012 Nov; 57(11):2873-82. PubMed ID: 22623043
[TBL] [Abstract][Full Text] [Related]
8. Deguelin promotes apoptosis and inhibits angiogenesis of gastric cancer.
Lee H; Lee JH; Jung KH; Hong SS
Oncol Rep; 2010 Oct; 24(4):957-63. PubMed ID: 20811676
[TBL] [Abstract][Full Text] [Related]
9. Deguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathway.
Murillo G; Peng X; Torres KE; Mehta RG
Cancer Prev Res (Phila); 2009 Nov; 2(11):942-50. PubMed ID: 19861542
[TBL] [Abstract][Full Text] [Related]
10. [Effects of deguelin on proliferation and apoptosis of MCF-7 breast cancer cells by phosphatidylinositol 3-kinase/Akt signaling pathway].
Chu ZH; Liang XH; Zhou XL; Huang RF; Zhan Qz; Jiang JW
Zhong Xi Yi Jie He Xue Bao; 2011 May; 9(5):533-8. PubMed ID: 21565140
[TBL] [Abstract][Full Text] [Related]
11. Deguelin Impairs Cell Adhesion, Migration and Invasion of Human Lung Cancer Cells through the NF-[Formula: see text]B Signaling Pathways.
Hsiao YT; Fan MJ; Huang AC; Lien JC; Lin JJ; Chen JC; Hsia TC; Wu RS; Chung JG
Am J Chin Med; 2018; 46(1):209-229. PubMed ID: 29402127
[TBL] [Abstract][Full Text] [Related]
12. Deguelin and Its Role in Chronic Diseases.
Boyd J; Han A
Adv Exp Med Biol; 2016; 929():363-375. PubMed ID: 27771933
[TBL] [Abstract][Full Text] [Related]
13. Deguelin inhibits the migration and invasion of lung cancer A549 and H460 cells via regulating actin cytoskeleton rearrangement.
Zhao H; Jiao Y; Zhang Z
Int J Clin Exp Pathol; 2015; 8(12):15582-90. PubMed ID: 26884827
[TBL] [Abstract][Full Text] [Related]
14. The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-kappaB pathway.
Dell'Eva R; Ambrosini C; Minghelli S; Noonan DM; Albini A; Ferrari N
Carcinogenesis; 2007 Feb; 28(2):404-13. PubMed ID: 16952909
[TBL] [Abstract][Full Text] [Related]
15. Deguelin inhibits the migration and invasion of U-2 OS human osteosarcoma cells via the inhibition of matrix metalloproteinase-2/-9 in vitro.
Shang HS; Chang JB; Lin JH; Lin JP; Hsu SC; Liu CM; Liu JY; Wu PP; Lu HF; Au MK; Chung JG
Molecules; 2014 Oct; 19(10):16588-608. PubMed ID: 25322282
[TBL] [Abstract][Full Text] [Related]
16. Deguelin induces apoptosis by targeting both EGFR-Akt and IGF1R-Akt pathways in head and neck squamous cell cancer cell lines.
Baba Y; Fujii M; Maeda T; Suzuki A; Yuzawa S; Kato Y
Biomed Res Int; 2015; 2015():657179. PubMed ID: 26075254
[TBL] [Abstract][Full Text] [Related]
17. Deguelin, an Akt inhibitor, suppresses IkappaBalpha kinase activation leading to suppression of NF-kappaB-regulated gene expression, potentiation of apoptosis, and inhibition of cellular invasion.
Nair AS; Shishodia S; Ahn KS; Kunnumakkara AB; Sethi G; Aggarwal BB
J Immunol; 2006 Oct; 177(8):5612-22. PubMed ID: 17015749
[TBL] [Abstract][Full Text] [Related]
18. Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway.
Bortul R; Tazzari PL; Billi AM; Tabellini G; Mantovani I; Cappellini A; Grafone T; Martinelli G; Conte R; Martelli AM
Br J Haematol; 2005 Jun; 129(5):677-86. PubMed ID: 15916691
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of deguelin-induced apoptosis in transformed human bronchial epithelial cells.
Lee HY
Biochem Pharmacol; 2004 Sep; 68(6):1119-24. PubMed ID: 15313408
[TBL] [Abstract][Full Text] [Related]
20. Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin.
Jin Q; Feng L; Behrens C; Bekele BN; Wistuba II; Hong WK; Lee HY
Cancer Res; 2007 Dec; 67(24):11630-9. PubMed ID: 18089792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
